<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232089</url>
  </required_header>
  <id_info>
    <org_study_id>CHTF919D2302</org_study_id>
    <nct_id>NCT00232089</nct_id>
  </id_info>
  <brief_title>Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia</brief_title>
  <official_title>Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is being done to evaluate the safety, tolerability and satisfactory relief of
      dyspepsia symptoms in females excluding those with predominant stomach pain. Tegaserod will
      be evaluated at 6mg twice daily and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Over 6 weeks of treatment assessment of percent of days with satisfactory relief of dyspepsia and/or average severity score in (average of postprandial fullness early satiety and bloating)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weekly assessment of satisfactory relief of dyspepsia.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily assessment of percentage of patients responding on average severity score.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For each week assessment of average daily severity score.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of days with satisfactory relief of dyspepsia during each week.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly global assessment of change in dyspepsia condition.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly assessment of individual symptoms score of postprandial fullness early satiety, bloating, abdominal pain, nausea and vomiting.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life at end of treatment compared to baseline.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability.</measure>
  </secondary_outcome>
  <enrollment>1296</enrollment>
  <condition>Dyspepsia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegaserod</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients, 18 years and older

          -  Self-reported presence of persistent or recurrent adverse digestive symptoms
             consistent with dyspepsia; for at least 12 weeks, not necessarily consecutive, during
             the previous 12 months.

        Exclusion Criteria:

          -  Abnormal esophago-gastro-duodenoscopy (EGD) endoscopy findings such as any esophageal
             mucosal break, gastric erosions, gastric ulcers and/or duodenal ulcers/erosions on an
             EDG exam performed with 12 weeks prior to baseline.

          -  Current or history of erosive esophagitis confirmed by EGD

          -  Heartburn occurring 3 or more days a week.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Chair</role>
    <affiliation>East Hanover NJ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936-108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2328</url>
    <description>Results for CHTF919D2302 from the Novartis Clinical Trials website</description>
  </link>
  <results_reference>
    <citation>Vakil N, Laine L, Talley NJ, Zakko SF, Tack J, Chey WD, Kralstein J, Earnest DL, Ligozio G, Cohard-Radice M. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol. 2008 Aug;103(8):1906-19. doi: 10.1111/j.1572-0241.2008.01953.x. Epub 2008 Jul 4.</citation>
    <PMID>18616658</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>October 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <keyword>Dyspepsia, gastrointestinal, tegaserod</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegaserod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

